Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
462
¥ millions (year-on-year change in operating income)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportSecond quarter of the fiscal year ending December 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales25,352 million yen+6.3%
Operating profit1,941 million yen+31.3%
Ordinary income1,938 million yen+37.8%
Net income1,203 million yen+41.4%
Gross Profit Margin24.7%
Operating profit margin7.7%
Selling, general and administrative expenses4,325 million yen
Results for the three months of the current quarter
Net Sales
12,758 million yen
Operating profit
953 million yen
Full-year earnings forecast
Net Sales
52,000 million yen
Operating profit
3,800 million yen
Ordinary income
3,800 million yen
Net income
2,300 million yen
Earnings per share
63.36 yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales
Business Expansion373
Changes in sales and price pass-through483
Foreign Exchange Effects637
Operating profit
Underlying change in revenue249
Change in cost ratio139
Change in SG&A expenses32
Business Expansion4
Foreign Exchange Effects38
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The economic environment in Japan and overseas, demand for products and services, foreign exchange rates and the stock market are identified as assumptions and risk factors. Numerical assumptions: Not disclosed.New initiatives
- Launch and expansion of sales for GeoJudge, a crane overturning risk assessment testing machine
- Launch of a new nutrunner
- Launch of organic solvent recycling equipment and separation membrane tubes
- Lower manufacturing costs through factory restructuring, a review of suppliers and mold improvements
- Commercialization of high-purity, bioabsorbable magnesium for medical applications and expansion into the medical-device field
Key KPIsA metric the company considers important as a management benchmark.
- Overseas revenue ratio33 %Year on year against the same period last year+4.1 percentage points
Segment results
Fastener Business
Net Sales
18,981 million yen+7.1%
Operating profit
1,334 million yen+50.5%
Industrial Machinery Business
Net Sales
2,923 million yen+4.8%
Operating profit
446 million yen+6.8%
Control Business
Net Sales
3,392 million yen+3.2%
Operating profit
222 million yen-3.4%
Medical Business
Net Sales
54 million yen-1.2%
Operating profit
-62 million yen
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Second quarter of the fiscal year ending December 2026 |
| Net Sales | 25,352 million yen (YoY +6.3%) |
| Operating profit | 1,941 million yen (YoY +31.3%) |
| Ordinary income | 1,938 million yen (YoY +37.8%) |
| Net income | 1,203 million yen (YoY +41.4%) |
| Gross Profit Margin | 24.7% |
| Operating profit margin | 7.7% |
| Selling, general and administrative expenses | 4,325 million yen |
| Results for the three months of the current quarter | Net Sales 12,758 million yen / Operating profit 953 million yen |
| Full-year earnings forecast | Net Sales 52,000 million yen / Operating profit 3,800 million yen / Ordinary income 3,800 million yen / Net income 2,300 million yen / Earnings per share 63.36 yen |
| Segment results | Fastener Business Net Sales 18,981 million yen (YoY +7.1%) / Operating profit 1,334 million yen (YoY +50.5%) / Industrial Machinery Business Net Sales 2,923 million yen (YoY +4.8%) / Operating profit 446 million yen (YoY +6.8%) / Control Business Net Sales 3,392 million yen (YoY +3.2%) / Operating profit 222 million yen (YoY -3.4%) / Medical Business Net Sales 54 million yen (YoY -1.2%) / Operating profit -62 million yen |
| Breakdown of Factors Affecting the Change | Net Sales Business Expansion 373 / Changes in sales and price pass-through 483 / Foreign Exchange Effects 637 / Operating profit Underlying change in revenue 249 / Change in cost ratio 139 / Change in SG&A expenses 32 / Business Expansion 4 / Foreign Exchange Effects 38 |
| Key KPIs | Indicator name Overseas revenue ratio / Value 33 % / Year on year against the same period last year +4.1 percentage points |
| Assumptions Underlying the Business Outlook | The economic environment in Japan and overseas, demand for products and services, foreign exchange rates and the stock market are identified as assumptions and risk factors. Numerical assumptions: Not disclosed. |
| New initiatives | Launch and expansion of sales for GeoJudge, a crane overturning risk assessment testing machine, Launch of a new nutrunner, Launch of organic solvent recycling equipment and separation membrane tubes, Lower manufacturing costs through factory restructuring, a review of suppliers and mold improvements, Commercialization of high-purity, bioabsorbable magnesium for medical applications and expansion into the medical-device field |
Items this document does not state (15)
Progress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in revenue, growth in high-value-added products for automobiles and data centers, lower manufacturing costs resulting from a review of suppliers and ordering methods, mold improvements and the promotion of in-house production, as well as a decline in selling, general and administrative expenses due to the reversal of the ¥286 million in M&A-related expenses recorded in the same period of the previous year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.